Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non-Small Cell Lung Cancer
Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases. Fortunately, the development of molecular oncology provides a promising and effective therapeutic s...
Saved in:
Main Authors: | Dehua Liao (Author), Lun Yu (Author), Dangang Shangguan (Author), Yongchang Zhang (Author), Bowen Xiao (Author), Ni Liu (Author), Nong Yang (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2022-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancements in understanding cardiotoxicity of EGFR- TKIs in non-small cell lung cancer treatment and beyond
by: Xin Li, et al.
Published: (2024) -
Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone
by: Yujia Wang, et al.
Published: (2021) -
Challenges of EGFR-TKIs in NSCLC and the potential role of herbs and active compounds: From mechanism to clinical practice
by: Xiaotong Song, et al.
Published: (2023) -
Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023) -
Primary Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs): Contexts and Comparisons in EGFR-Mutated Lung Cancer
by: Keigo Kobayashi
Published: (2023)